Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

BACKGROUND: The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we sought to broadly survey cancers to identify those in which the microbiome may play a prognostic role using retrospective analyses...

Descripción completa

Detalles Bibliográficos
Autores principales: Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S., Wang, Lei, Tinoco, Gabriel, Patel, Sandip H., Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P., Verschraegen, Claire F., Kendra, Kari L., Otterson, Gregory A., Li, Lang, Presley, Carolyn J., Owen, Dwight H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201618/
https://www.ncbi.nlm.nih.gov/pubmed/32375706
http://dx.doi.org/10.1186/s12885-020-06882-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201618/
https://www.ncbi.nlm.nih.gov/pubmed/32375706
http://dx.doi.org/10.1186/s12885-020-06882-6

Ejemplares similares